Valneva's S4V2 Shigella vaccine candidate meets primary endpoint in Phase 2 CHIM trial

Valneva said its S4V2 Shigella vaccine candidate met the primary endpoint in a Phase 2 CHIM trial, with a significant reduction in S. sonnei shigellosis incidence versus placebo. An infant trial showed favorable safety.

Detected & updated continuously · Source: Nebula